Our Partners

IMID-Bio-UK Network

 

IMID-Bio-UK is a network of academics, clinicians, charities and industry partners working together across the UK to inform and improve drug development and the stratification of therapeutic options for patients affected by IMIDs.  The investigator team, together with extensive supporting facilities and staff, offer the clinical, investigative, technical and analytical leadership skills necessary for the success of IMID-Bio-UK.

The combination of diverse IMID Stratified Medicine Consortia which includes multiple funders and pharma partners, collectively delivers deep knowledge of the IMID landscape and infrastructure, together with strong industry interactions. Several of our partners have collaborated over many years and have established a long-term, shared commitment to furnishing our precision medicine ambition to realise the promise of precision medicine approaches in IMID.

University of Glasgow

IMID-Bio-UK is led by Professor Iain McInnes, director of the Institute of Infection, Immunity and Inflammation at the University of Glasgow. In addition to being the chief investigator of the Scottish Early Rheumatoid Arthritis (SERA) inception cohort and biobank, Iain is also co-investigator in RA-MAP, Pathobiology of Early Arthritis Cohort (PEAC), Maximising Therapeutic Utility in Rheumatoid Arthritis (MATURA) and has lead numerous phase I-III clinical trials. He is Director of the ARUK Centre of Excellence in rheumatoid arthritis and the Institute of Infection, Immunity and Inflammation at the University of Glasgow. He is an authority on the pathogenesis and treatment of inflammatory arthritis. His early studies identified the expression and functional importance of a number of cytokines in rheumatoid synovitis and have extended since to explore the pathways that drive inflammation in the skin and joints of people with psoriatic arthritis.


Queen Mary University, London

Mike Barnes joined QMUL in January 2012 as the Director of Bioinformatics at the William Harvey Research Institute and is the leader of the data integration work streams of IMID-Bio-UK. He previously led a computational biology team at GlaxoSmithKline focused on translational research for neuroscience drug discovery. Michael is an investigator at the London Farr Institute and also serves on the board and exec of eMedLab, a groundbreaking cloud computing facility funded by the MRC. He is also a co-investigator on several stratified medicine projects, including Psoriasis Stratification to Optimise Relevant Therapy (PSORT), RA-MAP, Maximising Therapeutic Utility in Rheumatoid Arthritis (MATURA) and Treatment According to Response in Giant cEll arTeritis (TARGET).

Professor Costantino Pitzalis major research interests focuses on the cellular and molecular mechanisms of inflammation and autoimmunity in chronic arthritis applied in particular to rheumatoid and psoriatic arthritis. The emphasis is on translational research and biomarkers discovery and he is Director of an Arthritis Research UK Experimental Arthritis Treatment Centre at Barts dedicated to the development of new anti-arthritic drugs and experimental medicine. He leads a Research Team of approximately 50 Researchers (Clinicians and Scientists) supported by an active grant income over £14M and has published over 200 highly cited peer-reviewed papers (H-Index 47) in the field of inflammation, immunity and arthritis. He has written over 10 book Chapters including one published in the various editions of the Oxford Textbook of Rheumatology, currently in its 4th Edition, on “Synovial Pathology”.  He is Chief Investigator of the MRC/ARUK/NIHR biopsy-driven trials: PEACR4RAMATURA.


Newcastle University

Professor John Isaacs is Director of Newcastle University’s Institute for Cellular Medicine and Professor of Clinical Rheumatology. Additionally, he is Honorary Consultant Rheumatologist with the Newcastle upon Tyne Hospitals NHS Foundation Trust. John is internationally renowned as a pioneer of translational rheumatoid arthritis research, and is the Chief Investigator of the MRC/ABPI RA-MAP Consortium. He performs early phase experimental medicine studies, often using products developed in-house. His research interests include immunotherapy of rheumatic autoimmune disease, clinical therapeutic tolerance induction, pathogenesis and pharmacogenetics of rheumatoid arthritis.

David Jones is Professor of Liver Immunology for the Faculty of Medical Science at Newcastle University with a particular focus on the impact of the diseases on patients and how we can improve outcomes through the development and evaluation of new treatment approaches. Additionally, he is Honorary Consultant Hepatlogist with the Newcastle upon Tyne Hospitals NHS Foundation Trust. Dave also holds the position of NIHR Dean for Faculty Trainees, and is an NIHR Senior Investigator.  Dave has an international reputation for his work in autoimmune liver disease and leads the UK-PBC research consortium, which has the largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients.

Fai Ng is a Professor of Rheumatology at Newcastle University and the chief investigator of the Primary Sjögren’s Syndrome Registry. He qualified from Cambridge University and completed his postgraduate clinical training and PhD study in London. Fai’s research programme focuses on understanding the relationships between biological changes in primary Sjögren’s syndrome and clinical manifestations in particularly fatigue and stratified medicine. He is a co-director of the Newcastle Biomedicine Experimental Arthritis Treatment Centre and deputy director of the Clinical Research Facilities at Royal Victoria Infirmary.


University of Manchester

Professor Ian Bruce is a NIHR Senior Investigator at the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences. He is also Director of the NIHR Manchester Biomedical Research Centre and Centre Academic Lead for the NIHR Translational Research Partnership in Joint and Related Inflammatory Diseases. Ian is chief investigator for MAximizing Sle ThERapeutic PotentiaL by Application of  Novel and Stratified approaches (MASTERPLANS) clinical trial, the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) and the PRe-clinical EValuation of Novel Targets in RA (PREVENT RA) cohort.

Professor Christopher Griffiths is Foundation Chair in Dermatology at the University of Manchester in 1994 and is an honorary consultant dermatologist at Salford Royal NHS Foundation Trust. At the University of Manchester, he has held several posts including Faculty Research Dean and Director of the Manchester Academic Health Science Centre. He currently leads for precision medicine and the University in the DevoManc initiative. Chris is Chief Investigator of both the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) and British Association of Dermatologists Biologic Interventions Register (BADBIR). The latter is a biologics pharmacovigilance registry and bioresource, linked to PSORT and other national psoriasis cohort studies. He leads the precision medicine agenda for Health Innovation Manchester.

Professor Anthony Freemont is Director of MMPathIC (Manchester Molecular Pathology Innovation Centre), an MRC/EPSRC Molecular Pathology node which aims to take novel molecular pathology and molecular pathology related engineering discoveries into clinical use in partnership with industry. He is Professor and Honorary Consultant at Manchester University NHS Foundation Trust. His basic scientific and clinical research is focused in the broad area of molecular pathology and, in particular, the development and application of molecular pathology techniques to human skeletal tissues to obtain a better understanding of the molecular mechanisms underpinning disease.


University of Cambridge

Dr Richard Sandford, Honorary Consultant in medical genetics at Addenbrooke’s Hospital and Reader in Renal Genetics at Academic Department of Medical Genetics at the University of Cambridge, has a special interest in inherited renal and liver disease, the genetics of autoimmune liver disease and transformation of clinical genomic testing.

Dr George Mells is a Consultant Hepatlogist at Addenbrooke’s Hospital and Clinical Lecturer/Reader at Academic Department of Medical Genetics at the University of Cambridge specialising in renal genetics.

Richard and George, along with Dave Jones, lead a unique, world-leading, portfolio of autoimmune liver disease cohorts linked to the NIHR Rare Diseases – Translational Research Collaboration. They spearhead stratified hepatic medicine e.g. introducing a novel, second-line therapy for high-risk PBC into the clinic.


Industry Partners

Without the support of industry, it would not be possible for IMID-Bio-UK to integrate the activities and resources of many highly successful stratified medicine initiatives which are part of our ambitious project.

We are delighted to confirm Abbvie, Janssen, Novartis and QIAGEN have agreed to be founder industrial partners.

We enthusiastically welcome ongoing and future collaborations with industry.  If you would like to become an industry partner, please feel free to drop us an email to start the conversation.


Charity Partnership

We work with a range of charity partners from across the IMID landscape.  This will guide our development going forward  by helping to engage with the wider public and those affected by inflammatory mediated immune diseases.  IMID-Bio-UK is aligned with the strategic aims of our charity partners that broadly seek to impact patient outcomes via collaborative disease focussed discovery and translational research.

 

British Sjögren’s Syndrome Association exists to raise awareness of Sjögren's Syndrome and support research into its cause and treatment.  It is a self-help organisation with more than 2300 members, regional support groups throughout the UK whose members include sufferers and supporters who work together in helping one another cope with the day-to-day challenges of this debilitating and distressing condition.

LUPUS UK is the only national registered charity supporting people with systemic lupus and discoid lupus and assisting those approaching diagnosis. They more than 5500 Members and a number of Regional Groups around the UK who arrange medical talks, publish local newsletters, set up local occasions and organise fundraising events. 

National Rheumatoid Arthritis Society is the only patient-led organisation in the UK specialising in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Due to its targeted focus on RA and JIA, NRAS provides truly expert and wide-ranging services to support, educate and campaign for people living with these complex autoimmune conditions, their families and the health professionals who treat them.

The PBC Foundation is the only UK organisation exclusively dedicated to providing support and information to those affected by PBC. Their purpose is to have a positive impact on the lives of all those affected by PBC.

The Psoriasis Association are the leading national charity and membership organisation for people affected by psoriasis in the UK. Through their work, they help people whose lives are affected by psoriasis and psoriatic arthritis by funding research, providing information and raising awareness.

Use My Data is a movement of patients, carers and relatives which supports and promotes the protection of individual choice, freedom and privacy in the sharing of healthcare data to improve patient treatments and outcomes. 

Versus Arthritis (formerly known as Arthritis Research UK),  invests in breakthrough treatments, the best information and vital support for everyone affected by arthritis. Versus Arthritis believe that by harnessing the power of exceptional science, it is possible to overcome the pain, isolation and fatigue arthritis causes, making everyday life better for all people with arthritis in the UK.